CLEC4G

Across TCGA pan-cancer cohorts, CLEC4G Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CLEC4G data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CLEC4G Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CLEC4G expression acts as an unfavorable survival marker.

LIHC and LUSC are the cancer types where CLEC4G Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.011	0.784	<.001	24	view →
LUSC	DFS	Median	II,III,IV	0.185	0.717	.012	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CLEC4G–LIHC (OS)

Open the LIHC breakdown →